The FDA granted accelerated approval to Novo Nordisk’s Wegovy, a GLP-1 receptor agonist, for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), marking the drug as the first GLP-1 to enter this metabolic disease space. Approval is based on Phase 3 data demonstrating improvement in liver scarring and resolution of MASH. This expands a growing field of metabolic liver disease therapies, where Madrigal Pharmaceuticals’ Rezdiffra also competes. Analysts anticipate market shifts as physicians consider GLP-1s for MASH patients with underlying metabolic conditions, highlighting evolving treatment dynamics.